{"success":true,"data":{"pressRelease":{"id":"164063","rtpr_id":"nPn3Dd3ska-20261008","ticker":"ACB","exchange":"NASDAQ","all_tickers":["ACB"],"title":"Aurora Completes Major Expansion of European EU-GMP Manufacturing Facility, More Than Doubling Expected Annual Flower Output","author":"PR Newswire","published_at":"2026-10-08T11:05:00.630Z","article_body":"Aurora Completes Major Expansion of European EU-GMP Manufacturing Facility, More Than Doubling Expected Annual Flower Output\nPR Newswire\n\nEDMONTON, AB, Oct. 8, 2026\n\nNASDAQ | TSX: ACB\n\n * Multi-million-dollar investment results in increased domestic production\ncapacity in Germany, more than doubling expected annual flower output.\n * Enhanced facility adopts Aurora's proven cultivation practices and proprietary\ngenetics to support consistent, high-quality production.\n * Expanded EU-GMP manufacturing capacity reinforces Aurora's ability to deliver\ncompliant, high-quality products across European markets as demand increases.\nEDMONTON, AB, Oct. 8, 2026 /PRNewswire/ -- Aurora Cannabis Inc. (TSX: ACB)\n(NASDAQ: ACB), the leading Canadian-based global medical cannabis company,\ntoday announced the completion of a major expansion of its facility in Leuna,\nGermany. The expansion project establishes the Leuna facility as a\nmanufacturing site of excellence, incorporating proven cultivation and\npost-harvest practices from Aurora's Canadian operations alongside the\ncompany's proprietary genetics and product catalogue. The expanded facility\nhas increased cultivation capacity while improving product quality,\nconsistency and operational efficiency, strengthening the facility's role in\nserving Aurora's growth in Europe.\n\nTo commemorate the site's transformation and expanded role in Aurora's global\nEU-GMP manufacturing network, the facility has been renamed Aurora Horizon, a\nname selected by the local team, reflective of their pride and optimism for\nthe facility's future.\n\n\"The completion of our Leuna facility transformation is an important milestone\nfor Aurora and reinforces our commitment to serving patients in our\nfastest-growing markets, including Germany, where we are proud to be a\ndomestic manufacturer,\" said Alex Miller, EVP, Operations and Supply Chain at\nAurora. \"Now known as Aurora Horizon, the EU GMP-licensed facility\nstrengthens our ability to serve patients in Germany, while advancing our\nbroader European growth strategy. By bringing Aurora's proven cultivation and\noperational expertise and industry-leading genetics to Leuna, we have\nsignificantly advanced the site and our ability to drive growth in the\nregion.\"\n\nThe expanded facility has recently been granted an expanded EU-GMP license for\nthe newly built areas of the site, issued by the State Office for Social\nAffairs, Youth and Health of Saxony-Anhalt, and will support dynamic job\ncreation within the local vicinity.\n\nThe transformation of Aurora Horizon involved implementing the company's\nworld-class cultivation practices and methodologies, including lighting,\nirrigation, harvesting, and post-harvest processes, to ensure consistent and\nhigh-quality output. Aurora Horizon has successfully adopted Aurora's leading\nproprietary genetics from the company's global R&D facility, Aurora Coast\nin British Columbia, Canada. As a result, the facility is already meeting the\nhigh-performance thresholds of other sites within Aurora's network. The\nadditional capacity is expected to help Aurora meet growing demand for\nhigh-quality medical cannabis in Germany and across European markets, while\nimproving supply chain resilience and operational efficiency. As one of only\nthree in country producers, we are uniquely positioned to continue to\ncontribute with cultivation and manufacturing job creation in the\nSaxony-Anhalt region.\n\nAbout Aurora Cannabis Inc.\n\nAurora is Opening the World to Cannabis(™), serving both the medical and\nconsumer markets across Canada, Europe, Australia and New Zealand.\nHeadquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis,\ndedicated to helping people improve their lives. The Company's adult-use brand\nportfolio includes Drift(®), San Raf(®), Daily Special(™), Tasty's(™),\nBeing(®) and Greybeard(®). Medical cannabis brands include MedReleaf(®),\nCanniMed(®), Aurora(®) and Whistler Medical Marijuana Corporation(®), as\nwell as international brands, Pedanios(®), IndiMed(™) and CraftPlant(™).\nAurora also has a controlling interest in Bevo Farms Ltd., North America's\nleading supplier of propagated agricultural plants. Driven by science and\ninnovation, and with a focus on high-quality cannabis products, Aurora's\nbrands continue to break through as industry leaders in the medical, wellness\nand adult recreational markets wherever they are launched. Learn more\nat www.auroramj.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4791857-1&h=2428013122&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4295695-1%26h%3D3564663324%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D4128153-1%2526h%253D3697784588%2526u%253Dhttps%25253A%25252F%25252Fcan01.safelinks.protection.outlook.com%25252F%25253Furl%25253Dhttps%2525253A%2525252F%2525252Fc212.net%2525252Fc%2525252Flink%2525252F%2525253Ft%2525253D0%25252526l%2525253Den%25252526o%2525253D4095039-1%25252526h%2525253D2487444144%25252526u%2525253Dhttps%252525253A%252525252F%252525252Fwww.auroramj.com%252525252F%25252526a%2525253Dwww.auroramj.com%252526data%25253D05%2525257C02%2525257CLindsey.Soper%25252540auroramj.com%2525257C82ce931cfb4f40dbff9408dc399c6b4e%2525257C97ff2d32fc2f4ef0b838e1f27817796c%2525257C0%2525257C0%2525257C638448591171066619%2525257CUnknown%2525257CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%2525253D%2525257C0%2525257C%2525257C%2525257C%252526sdata%25253DhWz2RHtP6jEFOCxpxVGoQxyevZVQ0dCNvcGZAl2%2525252F1wo%2525253D%252526reserved%25253D0%2526a%253Dwww.auroramj.com%26a%3Dwww.auroramj.com&a=www.auroramj.com)\n and follow us on X\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4791857-1&h=1022567583&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4295695-1%26h%3D2085879903%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D4128153-1%2526h%253D2857970268%2526u%253Dhttps%25253A%25252F%25252Ftwitter.com%25252FAurora_MMJ%2526a%253DX%26a%3DX&a=X)\n and LinkedIn\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4791857-1&h=3870814624&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4295695-1%26h%3D1548729162%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D4128153-1%2526h%253D3400495928%2526u%253Dhttps%25253A%25252F%25252Fwww.linkedin.com%25252Fcompany%25252F6440508%25252Fadmin%25252Ffeed%25252Fposts%25252F%2526a%253DLinkedIn%26a%3DLinkedIn&a=LinkedIn)\n.\n\nAurora's common shares trade on the NASDAQ and TSX under the symbol \"ACB\".\n\nForward Looking Information\n\nThis news release includes statements containing certain \"forward-looking\ninformation\" within the meaning of applicable securities laws\n(\"forward-looking statements\"). Forward-looking statements are frequently\ncharacterized by words such as \"plan\", \"continue\", \"expect\", \"project\",\n\"intend\", \"believe\", \"anticipate\", \"estimate\", \"may\", \"will\", \"potential\",\n\"proposed\" and other similar words, or statements that certain events or\nconditions \"may\" or \"will\" occur. Forward-looking statements made in this news\nrelease include, but are not limited to, statements and information about the\ncompleted expansion of the Company's EU-GMP certified facility in Germany and\nrelated benefits including, but not limited to, increased cultivation\ncapacity, product quality, consistency, supply chain resilience, operational\nefficiency and local job creation; expectations for the annual flower output\nfrom that facility to more than double; the Company's ability to deliver\ncompliant, high-quality products across European markets as demand increases;\nfuture growth opportunities in Europe and particularly in Germany; and\nstatements regarding the Company's ability to drive and participate in growth\nin European markets.\n\nThese forward-looking statements are only predictions. Forward-looking\ninformation or statements contained in this news release have been developed\nbased on the Company and its management's good faith assumptions relating to\nthe financial, market, regulatory and other relevant environments that will\nexist and affect the Company's business and operations in the future.\nForward-looking information and statements are not a guarantee of future\nperformance and are based upon a number of estimates and assumptions of\nmanagement at the date the statements are made including, among other things,\nassumptions about: development costs remaining consistent with budgets; the\nability to manage anticipated and unanticipated costs; access to favorable\nequity and debt capital markets; the ability to raise sufficient capital to\nadvance the business of the Company; favorable operating and economic\nconditions; political and regulatory stability; obtaining and maintaining all\nrequired licenses and permits; receipt of governmental approvals and permits;\nsustained labour stability; stability in financial and capital goods markets;\nfavorable production levels and costs from the Company's operations; the\npricing of various cannabis products; the level of demand for cannabis\nproducts; the availability of third-party service providers and other inputs\nfor the Company's operations; and the Company's ability to conduct operations\nin a safe, efficient, and effective manner. The Company does not give any\nassurance that the assumptions on which forward-looking information or\nstatements are based will prove to be correct, or that the Company's business\nor operations will not be affected in any material manner by these or other\nfactors not foreseen or foreseeable by the Company or management or beyond the\nCompany's control. Such forward-looking statements are estimates reflecting\nthe Company's best judgment based upon current information and involve a\nnumber of risks and uncertainties, and there can be no assurance that other\nfactors will not affect the accuracy of such forward-looking statements. These\nrisks include, but are not limited to, the ability to retain key personnel,\nthe ability to continue investing in infrastructure to support growth, the\nability to obtain financing on acceptable terms, the continued quality of our\nproducts, customer experience and retention, the development of third party\ngovernment and non-government consumer sales channels, management's estimates\nof consumer demand in Canada and in jurisdictions where the Company exports,\nexpectations of future results and expenses, the availability of additional\ncapital to complete construction projects and facilities improvements, the\nrisk of successful integration of acquired business and operations,\nmanagement's estimation that SG&A will grow only in proportion to revenue\ngrowth, the ability to expand and maintain distribution capabilities, the\nimpact of competition, the general impact of financial market conditions, the\nyield from cannabis growing operations, product demand, changes in prices of\nrequired commodities, competition, and the possibility for changes in laws,\nrules, and regulations in the industry, epidemics, pandemics or other public\nhealth crisis, and other risks as set out under the heading \"Risk Factors\" in\nthe Company's annual information form dated June 10, 2026 (the \"AIF\") and\nfiled with Canadian securities regulators available on the Company's issuer\nprofile on SEDAR+ at www.sedarplus.com (http://www.sedarplus.com) and filed\nwith and available on the SEC's website at www.sec.gov (http://www.sec.gov) .\nThe Company cautions that the list of risks, uncertainties and other factors\ndescribed in the AIF is not exhaustive and other factors could also adversely\naffect its results. Readers are urged to consider the risks, uncertainties and\nassumptions carefully in evaluating the forward-looking statements and are\ncautioned not to place undue reliance on such information. The Company is\nunder no obligation, and expressly disclaims any intention or obligation, to\nupdate or revise any forward-looking statements, whether as a result of new\ninformation, future events or otherwise, except as expressly required by\napplicable securities laws.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/aurora-completes-major-expansion-of-european-eu-gmp-manufacturing-facility-more-than-doubling-expected-annual-flower-output-302901501.html\n(https://www.prnewswire.com/news-releases/aurora-completes-major-expansion-of-european-eu-gmp-manufacturing-facility-more-than-doubling-expected-annual-flower-output-302901501.html)\n\nSOURCE Aurora Cannabis Inc.\n\n\n\nFor Media: Michelle Lefler | VP, Communications & PR | media@auroramj.com; For Investors: ICR, Inc. | aurora@icrinc.com\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS2004326/Aurora-Cannabis-Inc-Aurora-Completes-Major-Expansion-of-Europea.jpg?id=OA2992576\nhttps://mmx.prnewswire.com/media/MS1136461/Aurora-Cannabis-Inc-Aurora-Completes-Major-Expansion-of-Europea.jpg?id=OA2992563\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn3Dd3ska-20261008","title":"Aurora Completes Major Expansion of European EU-GMP Manufacturing Facility, More Than Doubling Expected Annual Flower Output","author":"PR Newswire","ticker":"ACB","created":"2026-10-08T11:05:00.630Z","tickers":["ACB"],"exchange":"NASDAQ","article_body":"Aurora Completes Major Expansion of European EU-GMP Manufacturing Facility, More Than Doubling Expected Annual Flower Output\nPR Newswire\n\nEDMONTON, AB, Oct. 8, 2026\n\nNASDAQ | TSX: ACB\n\n * Multi-million-dollar investment results in increased domestic production\ncapacity in Germany, more than doubling expected annual flower output.\n * Enhanced facility adopts Aurora's proven cultivation practices and proprietary\ngenetics to support consistent, high-quality production.\n * Expanded EU-GMP manufacturing capacity reinforces Aurora's ability to deliver\ncompliant, high-quality products across European markets as demand increases.\nEDMONTON, AB, Oct. 8, 2026 /PRNewswire/ -- Aurora Cannabis Inc. (TSX: ACB)\n(NASDAQ: ACB), the leading Canadian-based global medical cannabis company,\ntoday announced the completion of a major expansion of its facility in Leuna,\nGermany. The expansion project establishes the Leuna facility as a\nmanufacturing site of excellence, incorporating proven cultivation and\npost-harvest practices from Aurora's Canadian operations alongside the\ncompany's proprietary genetics and product catalogue. The expanded facility\nhas increased cultivation capacity while improving product quality,\nconsistency and operational efficiency, strengthening the facility's role in\nserving Aurora's growth in Europe.\n\nTo commemorate the site's transformation and expanded role in Aurora's global\nEU-GMP manufacturing network, the facility has been renamed Aurora Horizon, a\nname selected by the local team, reflective of their pride and optimism for\nthe facility's future.\n\n\"The completion of our Leuna facility transformation is an important milestone\nfor Aurora and reinforces our commitment to serving patients in our\nfastest-growing markets, including Germany, where we are proud to be a\ndomestic manufacturer,\" said Alex Miller, EVP, Operations and Supply Chain at\nAurora. \"Now known as Aurora Horizon, the EU GMP-licensed facility\nstrengthens our ability to serve patients in Germany, while advancing our\nbroader European growth strategy. By bringing Aurora's proven cultivation and\noperational expertise and industry-leading genetics to Leuna, we have\nsignificantly advanced the site and our ability to drive growth in the\nregion.\"\n\nThe expanded facility has recently been granted an expanded EU-GMP license for\nthe newly built areas of the site, issued by the State Office for Social\nAffairs, Youth and Health of Saxony-Anhalt, and will support dynamic job\ncreation within the local vicinity.\n\nThe transformation of Aurora Horizon involved implementing the company's\nworld-class cultivation practices and methodologies, including lighting,\nirrigation, harvesting, and post-harvest processes, to ensure consistent and\nhigh-quality output. Aurora Horizon has successfully adopted Aurora's leading\nproprietary genetics from the company's global R&D facility, Aurora Coast\nin British Columbia, Canada. As a result, the facility is already meeting the\nhigh-performance thresholds of other sites within Aurora's network. The\nadditional capacity is expected to help Aurora meet growing demand for\nhigh-quality medical cannabis in Germany and across European markets, while\nimproving supply chain resilience and operational efficiency. As one of only\nthree in country producers, we are uniquely positioned to continue to\ncontribute with cultivation and manufacturing job creation in the\nSaxony-Anhalt region.\n\nAbout Aurora Cannabis Inc.\n\nAurora is Opening the World to Cannabis(™), serving both the medical and\nconsumer markets across Canada, Europe, Australia and New Zealand.\nHeadquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis,\ndedicated to helping people improve their lives. The Company's adult-use brand\nportfolio includes Drift(®), San Raf(®), Daily Special(™), Tasty's(™),\nBeing(®) and Greybeard(®). Medical cannabis brands include MedReleaf(®),\nCanniMed(®), Aurora(®) and Whistler Medical Marijuana Corporation(®), as\nwell as international brands, Pedanios(®), IndiMed(™) and CraftPlant(™).\nAurora also has a controlling interest in Bevo Farms Ltd., North America's\nleading supplier of propagated agricultural plants. Driven by science and\ninnovation, and with a focus on high-quality cannabis products, Aurora's\nbrands continue to break through as industry leaders in the medical, wellness\nand adult recreational markets wherever they are launched. Learn more\nat www.auroramj.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4791857-1&h=2428013122&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4295695-1%26h%3D3564663324%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D4128153-1%2526h%253D3697784588%2526u%253Dhttps%25253A%25252F%25252Fcan01.safelinks.protection.outlook.com%25252F%25253Furl%25253Dhttps%2525253A%2525252F%2525252Fc212.net%2525252Fc%2525252Flink%2525252F%2525253Ft%2525253D0%25252526l%2525253Den%25252526o%2525253D4095039-1%25252526h%2525253D2487444144%25252526u%2525253Dhttps%252525253A%252525252F%252525252Fwww.auroramj.com%252525252F%25252526a%2525253Dwww.auroramj.com%252526data%25253D05%2525257C02%2525257CLindsey.Soper%25252540auroramj.com%2525257C82ce931cfb4f40dbff9408dc399c6b4e%2525257C97ff2d32fc2f4ef0b838e1f27817796c%2525257C0%2525257C0%2525257C638448591171066619%2525257CUnknown%2525257CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%2525253D%2525257C0%2525257C%2525257C%2525257C%252526sdata%25253DhWz2RHtP6jEFOCxpxVGoQxyevZVQ0dCNvcGZAl2%2525252F1wo%2525253D%252526reserved%25253D0%2526a%253Dwww.auroramj.com%26a%3Dwww.auroramj.com&a=www.auroramj.com)\n and follow us on X\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4791857-1&h=1022567583&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4295695-1%26h%3D2085879903%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D4128153-1%2526h%253D2857970268%2526u%253Dhttps%25253A%25252F%25252Ftwitter.com%25252FAurora_MMJ%2526a%253DX%26a%3DX&a=X)\n and LinkedIn\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4791857-1&h=3870814624&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4295695-1%26h%3D1548729162%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D4128153-1%2526h%253D3400495928%2526u%253Dhttps%25253A%25252F%25252Fwww.linkedin.com%25252Fcompany%25252F6440508%25252Fadmin%25252Ffeed%25252Fposts%25252F%2526a%253DLinkedIn%26a%3DLinkedIn&a=LinkedIn)\n.\n\nAurora's common shares trade on the NASDAQ and TSX under the symbol \"ACB\".\n\nForward Looking Information\n\nThis news release includes statements containing certain \"forward-looking\ninformation\" within the meaning of applicable securities laws\n(\"forward-looking statements\"). Forward-looking statements are frequently\ncharacterized by words such as \"plan\", \"continue\", \"expect\", \"project\",\n\"intend\", \"believe\", \"anticipate\", \"estimate\", \"may\", \"will\", \"potential\",\n\"proposed\" and other similar words, or statements that certain events or\nconditions \"may\" or \"will\" occur. Forward-looking statements made in this news\nrelease include, but are not limited to, statements and information about the\ncompleted expansion of the Company's EU-GMP certified facility in Germany and\nrelated benefits including, but not limited to, increased cultivation\ncapacity, product quality, consistency, supply chain resilience, operational\nefficiency and local job creation; expectations for the annual flower output\nfrom that facility to more than double; the Company's ability to deliver\ncompliant, high-quality products across European markets as demand increases;\nfuture growth opportunities in Europe and particularly in Germany; and\nstatements regarding the Company's ability to drive and participate in growth\nin European markets.\n\nThese forward-looking statements are only predictions. Forward-looking\ninformation or statements contained in this news release have been developed\nbased on the Company and its management's good faith assumptions relating to\nthe financial, market, regulatory and other relevant environments that will\nexist and affect the Company's business and operations in the future.\nForward-looking information and statements are not a guarantee of future\nperformance and are based upon a number of estimates and assumptions of\nmanagement at the date the statements are made including, among other things,\nassumptions about: development costs remaining consistent with budgets; the\nability to manage anticipated and unanticipated costs; access to favorable\nequity and debt capital markets; the ability to raise sufficient capital to\nadvance the business of the Company; favorable operating and economic\nconditions; political and regulatory stability; obtaining and maintaining all\nrequired licenses and permits; receipt of governmental approvals and permits;\nsustained labour stability; stability in financial and capital goods markets;\nfavorable production levels and costs from the Company's operations; the\npricing of various cannabis products; the level of demand for cannabis\nproducts; the availability of third-party service providers and other inputs\nfor the Company's operations; and the Company's ability to conduct operations\nin a safe, efficient, and effective manner. The Company does not give any\nassurance that the assumptions on which forward-looking information or\nstatements are based will prove to be correct, or that the Company's business\nor operations will not be affected in any material manner by these or other\nfactors not foreseen or foreseeable by the Company or management or beyond the\nCompany's control. Such forward-looking statements are estimates reflecting\nthe Company's best judgment based upon current information and involve a\nnumber of risks and uncertainties, and there can be no assurance that other\nfactors will not affect the accuracy of such forward-looking statements. These\nrisks include, but are not limited to, the ability to retain key personnel,\nthe ability to continue investing in infrastructure to support growth, the\nability to obtain financing on acceptable terms, the continued quality of our\nproducts, customer experience and retention, the development of third party\ngovernment and non-government consumer sales channels, management's estimates\nof consumer demand in Canada and in jurisdictions where the Company exports,\nexpectations of future results and expenses, the availability of additional\ncapital to complete construction projects and facilities improvements, the\nrisk of successful integration of acquired business and operations,\nmanagement's estimation that SG&A will grow only in proportion to revenue\ngrowth, the ability to expand and maintain distribution capabilities, the\nimpact of competition, the general impact of financial market conditions, the\nyield from cannabis growing operations, product demand, changes in prices of\nrequired commodities, competition, and the possibility for changes in laws,\nrules, and regulations in the industry, epidemics, pandemics or other public\nhealth crisis, and other risks as set out under the heading \"Risk Factors\" in\nthe Company's annual information form dated June 10, 2026 (the \"AIF\") and\nfiled with Canadian securities regulators available on the Company's issuer\nprofile on SEDAR+ at www.sedarplus.com (http://www.sedarplus.com) and filed\nwith and available on the SEC's website at www.sec.gov (http://www.sec.gov) .\nThe Company cautions that the list of risks, uncertainties and other factors\ndescribed in the AIF is not exhaustive and other factors could also adversely\naffect its results. Readers are urged to consider the risks, uncertainties and\nassumptions carefully in evaluating the forward-looking statements and are\ncautioned not to place undue reliance on such information. The Company is\nunder no obligation, and expressly disclaims any intention or obligation, to\nupdate or revise any forward-looking statements, whether as a result of new\ninformation, future events or otherwise, except as expressly required by\napplicable securities laws.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/aurora-completes-major-expansion-of-european-eu-gmp-manufacturing-facility-more-than-doubling-expected-annual-flower-output-302901501.html\n(https://www.prnewswire.com/news-releases/aurora-completes-major-expansion-of-european-eu-gmp-manufacturing-facility-more-than-doubling-expected-annual-flower-output-302901501.html)\n\nSOURCE Aurora Cannabis Inc.\n\n\n\nFor Media: Michelle Lefler | VP, Communications & PR | media@auroramj.com; For Investors: ICR, Inc. | aurora@icrinc.com\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS2004326/Aurora-Cannabis-Inc-Aurora-Completes-Major-Expansion-of-Europea.jpg?id=OA2992576\nhttps://mmx.prnewswire.com/media/MS1136461/Aurora-Cannabis-Inc-Aurora-Completes-Major-Expansion-of-Europea.jpg?id=OA2992563\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-10-08T11:05:00.685771195Z","server_sent_at_ms":1791457500685},"received_at":"2026-10-08T11:05:00.741Z","source_url":"https://www.prnewswire.com/news-releases/aurora-completes-major-expansion-of-european-eu-gmp-manufacturing-facility-more-than-doubling-expected-annual-flower-output-302901501.html"},"analysis":{"id":"152498","press_release_id":"164063","analysis_json":{"industry":{"label":"Consumer Staples Distribution & Retail","sector":"Consumer Staples"},"redFlags":["investment size described only as 'multi-million-dollar' with no precise figure disclosed","output doubling is a forward-looking expectation, not a realized result"],"eventType":"operations_update","narrative":"Aurora Cannabis completed a major expansion of its EU-GMP facility in Leuna, Germany, renamed Aurora Horizon, more than doubling expected annual flower output at the site.\n\nThe expanded facility received an expanded EU-GMP license from Saxony-Anhalt authorities and now applies Aurora's Canadian cultivation practices and proprietary genetics from its Aurora Coast R&D site in British Columbia.\n\nAs one of only three domestic producers in Germany, Aurora positions the site to serve its fastest-growing market and strengthen European supply chain resilience; no specific financial figures for the investment were disclosed.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Domestic German capacity doubles via Aurora Horizon -- incremental positive for European medical cannabis growth but light on financials."},"keyFigures":{"customDimensions":{"eu_gmp_license":"expanded EU-GMP license granted for newly built areas","expected_flower_output":"more than doubling expected annual output"}},"quotedText":"The completion of our Leuna facility transformation is an important milestone for Aurora and reinforces our commitment to serving patients in our fastest-growing markets, including Germany, where we are proud to be a domestic manufacturer","namedEntities":{"people":[{"name":"Alex Miller","role":"EVP, Operations and Supply Chain"},{"name":"Michelle Lefler","role":"VP, Communications & PR"}],"products":["Aurora Horizon","Drift","San Raf","Daily Special","Tasty's","Being","Greybeard","MedReleaf","CanniMed","Aurora","Whistler Medical Marijuana Corporation","Pedanios","IndiMed","CraftPlant"],"companies":[{"name":"Aurora Cannabis Inc.","ticker":"ACB","relationship":"filer"},{"name":"Bevo Farms Ltd.","relationship":"controlled subsidiary"},{"name":"ICR, Inc.","relationship":"investor relations"},{"name":"State Office for Social Affairs, Youth and Health of Saxony-Anhalt","relationship":"regulator"}],"dollarAmounts":[{"amount":"multi-million-dollar","context":"investment in Leuna facility expansion (no precise figure given)"}]},"materialImpact":{"score":2,"reasoning":"Completion of a multi-million-dollar facility expansion in Germany more than doubling expected annual flower output supports European growth, but no revenue, cost, or timeline figures are disclosed; it is a capacity update, not a market-moving event."},"tickerRelevance":{"others":[],"primary":"ACB"},"globalImportance":25,"audienceRelevance":30,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap","eventGravity":"capacity expansion","sectorWeight":"cannabis, retail-interest","retailFavoriteBoost":"moderate (ACB is a retail-followed cannabis name)"}},"event_type":"operations_update","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Aurora Cannabis completed a major expansion of its EU-GMP facility in Leuna, Germany, renamed Aurora Horizon, more than doubling expected annual flower output at the site.\n\nThe expanded facility received an expanded EU-GMP license from Saxony-Anhalt authorities and now applies Aurora's Canadian cultivation practices and proprietary genetics from its Aurora Coast R&D site in British Columbia.\n\nAs one of only three domestic producers in Germany, Aurora positions the site to serve its fastest-growing market and strengthen European supply chain resilience; no specific financial figures for the investment were disclosed.","key_figures":{"customDimensions":{"eu_gmp_license":"expanded EU-GMP license granted for newly built areas","expected_flower_output":"more than doubling expected annual output"}},"named_entities":{"people":[{"name":"Alex Miller","role":"EVP, Operations and Supply Chain"},{"name":"Michelle Lefler","role":"VP, Communications & PR"}],"products":["Aurora Horizon","Drift","San Raf","Daily Special","Tasty's","Being","Greybeard","MedReleaf","CanniMed","Aurora","Whistler Medical Marijuana Corporation","Pedanios","IndiMed","CraftPlant"],"companies":[{"name":"Aurora Cannabis Inc.","ticker":"ACB","relationship":"filer"},{"name":"Bevo Farms Ltd.","relationship":"controlled subsidiary"},{"name":"ICR, Inc.","relationship":"investor relations"},{"name":"State Office for Social Affairs, Youth and Health of Saxony-Anhalt","relationship":"regulator"}],"dollarAmounts":[{"amount":"multi-million-dollar","context":"investment in Leuna facility expansion (no precise figure given)"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-08T11:05:08.308Z","global_importance":25,"audience_relevance":30,"importance_components":{"tickerTier":"mid-cap","eventGravity":"capacity expansion","sectorWeight":"cannabis, retail-interest","retailFavoriteBoost":"moderate (ACB is a retail-followed cannabis name)"}},"durationMs":6432,"modelName":"glm-5.3-flashx"}}